Abstract

The trimeric serine protease HTRA1 is a genetic risk factor associated with geographic atrophy (GA), a currently untreatable form of age-related macular degeneration. Here, we describe the allosteric inhibition mechanism of HTRA1 by a clinical Fab fragment, currently being evaluated for GA treatment. Using cryo-EM, X-ray crystallography and biochemical assays we identify the exposed LoopA of HTRA1 as the sole Fab epitope, which is approximately 30 Å away from the active site. The cryo-EM structure of the HTRA1:Fab complex in combination with molecular dynamics simulations revealed that Fab binding to LoopA locks HTRA1 in a non-competent conformational state, incapable of supporting catalysis. Moreover, grafting the HTRA1-LoopA epitope onto HTRA2 and HTRA3 transferred the allosteric inhibition mechanism. This suggests a conserved conformational lock mechanism across the HTRA family and a critical role of LoopA for catalysis, which was supported by the reduced activity of HTRA1-3 upon LoopA deletion or perturbation. This study reveals the long-range inhibition mechanism of the clinical Fab and identifies an essential function of the exposed LoopA for activity of HTRA family proteases.

The protease HTRA1 is a genetic risk factor for geographic atrophy. Here, Gerhardy et al. describe its inhibition by a clinical Fab, whose binding locks it in an inactive state. The mechanism identifies an essential function of LoopA with this protease family.

Details

Title
Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration
Author
Gerhardy, Stefan 1   VIAFID ORCID Logo  ; Ultsch, Mark 2 ; Tang, Wanjian 1   VIAFID ORCID Logo  ; Green, Evan 2 ; Holden, Jeffrey K. 1 ; Li, Wei 1 ; Estevez, Alberto 2 ; Arthur, Chris 2 ; Tom, Irene 3 ; Rohou, Alexis 2   VIAFID ORCID Logo  ; Kirchhofer, Daniel 1   VIAFID ORCID Logo 

 Genentech Inc., Department of Early Discovery Biochemistry, San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718) 
 Genentech Inc., Department of Structural Biology, San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718) 
 Genentech Inc., Department of OMNI Biomarker Development, San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2709802145
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.